{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:31:44Z","timestamp":1788496304625,"version":"build-2803163510"},"reference-count":212,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02611-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T02:28:29Z","timestamp":1751336909000},"page":"2199-2228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Experts\u2019 consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-5087","authenticated-orcid":false,"given":"Giampiero Igli","family":"Baroncelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3441-2014","authenticated-orcid":false,"given":"Marco","family":"Barale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1634-951X","authenticated-orcid":false,"given":"Valentina","family":"Camozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4477-4935","authenticated-orcid":false,"given":"Silvia","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6819-605X","authenticated-orcid":false,"given":"Manuela Caruso","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6622-4267","authenticated-orcid":false,"given":"Elena","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-9547","authenticated-orcid":false,"given":"Filomena","family":"Cetani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-9733","authenticated-orcid":false,"given":"Pasquale","family":"Comberiati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4492-4585","authenticated-orcid":false,"given":"Natascia Di","family":"Iorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6805-5804","authenticated-orcid":false,"given":"Cristina","family":"Eller-Vainicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-3468","authenticated-orcid":false,"given":"Francesco","family":"Emma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0103-7951","authenticated-orcid":false,"given":"Danilo","family":"Fintini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-9749","authenticated-orcid":false,"given":"Sandro","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-2468","authenticated-orcid":false,"given":"Laura","family":"Gianotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6343-4768","authenticated-orcid":false,"given":"Anna","family":"Grandone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7236-0713","authenticated-orcid":false,"given":"Giorgia","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4781-6715","authenticated-orcid":false,"given":"Stefano","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3899-0391","authenticated-orcid":false,"given":"Francesca","family":"Pigliaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2753-9230","authenticated-orcid":false,"given":"Marco","family":"Pitea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0751-3798","authenticated-orcid":false,"given":"Massimo","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8169-0696","authenticated-orcid":false,"given":"Vincenzo","family":"Rochira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8899-684X","authenticated-orcid":false,"given":"Rosaria Maddalena","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-7201","authenticated-orcid":false,"given":"Barbara","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2259-4685","authenticated-orcid":false,"given":"Stefano","family":"Stagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5693","authenticated-orcid":false,"given":"Giuseppe","family":"Vezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8140-3175","authenticated-orcid":false,"given":"Sabrina","family":"Corbetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2611_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK (2009) Incidence and prevalence of nutritional and hereditary rickets in Southern Denmark. Eur J Endocrinol 160:491\u2013497. https:\/\/doi.org\/10.1530\/EJE-08-0818","journal-title":"Eur J Endocrinol"},{"key":"2611_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen S, Johansson S, Raeder H, Bjerknes R (2016) Hereditary hypophosphatemia in Norway: a retrospective population- based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol 174:125\u2013136. https:\/\/doi.org\/10.1530\/EJE-15-0515","journal-title":"Eur J Endocrinol"},{"key":"2611_CR3","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","volume":"105","author":"S Hawley","year":"2020","unstructured":"Hawley S, Shaw NJ, Delmestri A, Prieto-Alhambra D, Cooper C, Pinedo-Villanueva R, Javaid MK (2020) Prevalence and mortality of individuals with X-linked hypophosphatemia: a united kingdom real-world data analysis. J Clin Endocrinol Metab 105:e871\u2013e878. https:\/\/doi.org\/10.1210\/clinem\/dgz203","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116791","volume":"173","author":"JL Sandy","year":"2023","unstructured":"Sandy JL, Nunez C, Wheeler BJ, Jefferies C, Morris A, Siafarikas A, Rodda CP, Simm P, Biggin A, Aum S, Elliot EJ, Munns CF (2023) Prevalence and characteristics of paediatric X-linked hypophosphataemia in Australia and New Zealand: results from the Australian and the New Zealand Paediatric Surveillance Units survey. Bone 173:116791. https:\/\/doi.org\/10.1016\/j.bone.2023.116791","journal-title":"Bone"},{"key":"2611_CR5","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s12020-024-03793-5","volume":"85","author":"S Crisafulli","year":"2024","unstructured":"Crisafulli S, Ingrasciotta Y, Vitturi G, Fontana A, L\u2019Abbate L, Alessi Y, Ferra\u00f9 F, Cantarutti L, Lazzerini D, Cannav\u00f2 S, Trifir\u00f2 G (2024) Epidemiological analysis to identify predictors of X-linked hypophosphatemia (XLH) diagnosis in an Italian pediatric population: the EPIX project. Endocrine 85:894\u2013905. https:\/\/doi.org\/10.1007\/s12020-024-03793-5","journal-title":"Endocrine"},{"key":"2611_CR6","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00467-024-06395-5","volume":"39","author":"R Wilson","year":"2024","unstructured":"Wilson R, Mukherjee-Roy N, Gattineni J (2024) The role of fibroblast growth factor 23 in regulation of phosphate balance. Pediatr Nephrol 39:3439\u20133451. https:\/\/doi.org\/10.1007\/s00467-024-06395-5","journal-title":"Pediatr Nephrol"},{"key":"2611_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, de Lucas CC, Schnabel D, Jandhyala R, M\u00e4kitie O (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis 14:58. https:\/\/doi.org\/10.1186\/s13023-019-1014-8","journal-title":"Orphanet J Rare Dis"},{"key":"2611_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s10354-019-00732-2","volume":"170","author":"A Raimann","year":"2020","unstructured":"Raimann A, Mindler GT, Kocijan R, Bekes K, Zwerina J, Haeusler G, Ganger R (2020) Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives. Wien Med Wochenschr 170:116\u2013123. https:\/\/doi.org\/10.1007\/s10354-019-00732-2","journal-title":"Wien Med Wochenschr"},{"key":"2611_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11657-021-00879-9","volume":"16","author":"F Al Juraibah","year":"2021","unstructured":"Al Juraibah F, Al Amiri E, Al Dubayee M, Al Jubeh J, Al Kandari H, Al Sagheir A, Al Shaikn A, Beshyah SA, Deeb A, Habeb A, Mustafa M, Zidan H, Mughal MZ (2021) Diagnosis and mangement of X-linked hypophosphatemia in children and adolescents in the Gulf Cooperation Council countries. Arch Osteop 16:52. https:\/\/doi.org\/10.1007\/s11657-021-00879-9","journal-title":"Arch Osteop"},{"key":"2611_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.641543","volume":"12","author":"MR Laurent","year":"2021","unstructured":"Laurent MR, De Schepper J, Trouet D, Godefroid N, Boros E, Heinrichs C, Bravenboer B, Velkeniers B, Lammens J, Harvengt P, Cavalier E, Kaux JF et al (2021) Consensus recommendations for the diagnosis and management of X-linked hypophosphatemia in Belgium. Front Endocrinol 12:641543. https:\/\/doi.org\/10.3389\/fendo.2021.641543","journal-title":"Front Endocrinol"},{"key":"2611_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.688309","volume":"12","author":"GI Baroncelli","year":"2021","unstructured":"Baroncelli GI, Mora S (2021) X-linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management. Front Endocrinol 12:688309. https:\/\/doi.org\/10.3389\/fendo.2021.688309","journal-title":"Front Endocrinol"},{"key":"2611_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10744","volume":"7","author":"CF Munns","year":"2023","unstructured":"Munns CF, Yoo HW, Jalaludin MY, Vasanwala R, Chandran M, Rhee Y, BUT WM, Pik-Shan Kong A, Numbenjapon N, Namba N, Imanishi Y, Clifton-Bligh RJ, Luo X, Xia W, (2023) Asia-Pacific consensus recommendations on X-linked hypophosphatemia: diagnosis, multidisciplinary management, and transition from pediatric to adult care. JBMR Plus 7:e10744. https:\/\/doi.org\/10.1002\/jbm4.10744","journal-title":"JBMR Plus"},{"key":"2611_CR13","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(24)01305-9","volume":"404","author":"P Kamenick\u00fd","year":"2024","unstructured":"Kamenick\u00fd P, Briot K, Munns CF, Linglart A (2024) X-linked hypophosphataemia. Lancet 404:887\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(24)01305-9","journal-title":"Lancet"},{"key":"2611_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","volume":"21","author":"D Haffner","year":"2025","unstructured":"Haffner D, Emma F, Seefried L, H\u00f6gler W, Javaid KM, Bockenhauer D, Bacchetta J, Eastwood D, Duplan MB, Schnabel D, Wicart P, Ariceta G et al (2025) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 21:330\u2013354. https:\/\/doi.org\/10.1038\/s41581-024-00926-x","journal-title":"Nat Rev Nephrol"},{"key":"2611_CR15","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf093","author":"DS Ali","year":"2025","unstructured":"Ali DS, Carpenter TO, Imel EA, Ward LM, Appelman-Dijkstra NM, Chaussain C, Jan de Beur SM, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F et al (2025) X-linked hypophosphatemia management in children: an International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaf093","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf011","author":"DS Ali","year":"2025","unstructured":"Ali DS, Mirza RD, Hussein S, Alsarraf F, Alexander RT, Abu Alrob H, Appelman-Dijkstra NM, Biosse-Duplan M, Brandi ML, Carpenter TO, Chaussain C, Dandurand K et al (2025) Systematic review: efficacy of medical therapy on outcomes important to pediatric patients with X-linked hypophosphatemia. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaf011","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bone.2015.05.040","volume":"79","author":"S Capelli","year":"2015","unstructured":"Capelli S, Donghi V, Maruca K, Vezzoli G, Corbetta S, Brandi ML, Mora S, Weber G (2015) Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets. Bone 79:143\u2013149. https:\/\/doi.org\/10.1016\/j.bone.2015.05.040","journal-title":"Bone"},{"key":"2611_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bone.2019.01.021","volume":"121","author":"C Zhang","year":"2019","unstructured":"Zhang C, Zhao Z, Sun Y, Xu L, JiaJue R, Cui L, Pang Q, Jiang Y, Li M, Wang O, He X, He S et al (2019) Clinical and genetic analysis in a large chinese cohort of patients with X-linked hypophosphatemia. Bone 121:212\u2013220. https:\/\/doi.org\/10.1016\/j.bone.2019.01.021","journal-title":"Bone"},{"key":"2611_CR19","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume- Czitrom S, Kamenicky P, Nevoux J, Pri\u00e9 D, Rothenbuhler A, Wicart P, Harvengt P (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3:R13-30. https:\/\/doi.org\/10.1530\/EC-13-0103","journal-title":"Endocr Connect"},{"key":"2611_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.03.009","volume":"103S","author":"A Rothenbuhler","year":"2020","unstructured":"Rothenbuhler A, Schnabel D, H\u00f6gler W, Linglart A (2020) Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Metabolism 103S:153892. https:\/\/doi.org\/10.1016\/j.metabol.2019.03.009","journal-title":"Metabolism"},{"key":"2611_CR21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00247-007-0503-4","volume":"37","author":"G Currarino","year":"2007","unstructured":"Currarino G (2007) Sagittal synostosis in X-linked hypophosphatemic rickets and related diseases. Pediatr Radiol 37:805\u2013812. https:\/\/doi.org\/10.1007\/s00247-007-0503-4","journal-title":"Pediatr Radiol"},{"key":"2611_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10728","volume":"7","author":"CF Munns","year":"2023","unstructured":"Munns CF, Maguire EP, Williams A, Wood S, Biggin A (2023) Craniosynostosis in patients with X-linked hypophosphatemia: a review. JBMR Plus 7:e10728. https:\/\/doi.org\/10.1002\/jbm4.10728","journal-title":"JBMR Plus"},{"key":"2611_CR23","doi-asserted-by":"publisher","first-page":"1422356","DOI":"10.3389\/fendo.2024.1422356","volume":"15","author":"A Stauffer","year":"2024","unstructured":"Stauffer A, Raimann A, Penzkofer S, Ganger R, Radler C, Mindler GT (2024) Lower limb maltorsion and acetabular deformity in children and adolescents with X-linked hypophosphatemia. Front Endocrinol 15:1422356. https:\/\/doi.org\/10.3389\/fendo.2024.1422356","journal-title":"Front Endocrinol"},{"key":"2611_CR24","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1210\/clinem\/dgae069","volume":"109","author":"F Boardman-Pretty","year":"2024","unstructured":"Boardman-Pretty F, Clift AK, Mahon H, Sawoky N, Mughal MZ (2024) The diagnostic odyssey in children and adolescents with X-linked hypophosphatemia: population-based, case-control study. J Clin Endocrinol Metab 109:2012\u20132018. https:\/\/doi.org\/10.1210\/clinem\/dgae069","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00439-009-0631-z","volume":"125","author":"C Gaucher","year":"2009","unstructured":"Gaucher C, Walrant-Debray O, Nguyen TM, Esterle L, Garab\u00e9dian M, Jehan F (2009) PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. Hum Genet 125:401\u2013411. https:\/\/doi.org\/10.1007\/s00439-009-0631-z","journal-title":"Hum Genet"},{"key":"2611_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1471-2350-12-116","volume":"12","author":"M Morey","year":"2011","unstructured":"Morey M, Castro-Feij\u00f3o L, Barreiro J, Cabanas P, Pombo M, Gil M, Bernabeu I, D\u00edaz-Grande JM, Rey-Cordo L, Ariceta G, Rica I, Nieto J et al (2011) Genetic diagnosis of X-linked dominant hypophosphatemic rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type. BMC Med Genet 12:116. https:\/\/doi.org\/10.1186\/1471-2350-12-116","journal-title":"BMC Med Genet"},{"key":"2611_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","volume":"32","author":"L Seefried","year":"2020","unstructured":"Seefried L, Smyth M, Keen R, Harvengt P (2020) Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. Osteop Int 32:7\u201322. https:\/\/doi.org\/10.1007\/s00198-020-05548-0","journal-title":"Osteop Int"},{"key":"2611_CR28","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00198-021-05997-1","volume":"32","author":"S Giannini","year":"2021","unstructured":"Giannini S, Bianchi ML, Rendina D, Massoletti P, Lazzerrini D, Brandi ML (2021) Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review Osteop Int 32:1937\u20131949. https:\/\/doi.org\/10.1007\/s00198-021-05997-1","journal-title":"A comprehensive review Osteop Int"},{"key":"2611_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-15-0661","volume":"174","author":"H Che","year":"2016","unstructured":"Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, Briot K (2016) Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol 174:325\u2013333. https:\/\/doi.org\/10.1530\/EJE-15-0661","journal-title":"Eur J Endocrinol"},{"key":"2611_CR30","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab070","author":"M Cheung","year":"2021","unstructured":"Cheung M, Rylands AJ, Williams A, Bailey K, Bubbear J (2021) Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course. J Endocr Soc. https:\/\/doi.org\/10.1210\/jendso\/bvab070","journal-title":"J Endocr Soc"},{"key":"2611_CR31","doi-asserted-by":"publisher","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","volume":"107","author":"MK Javaid","year":"2022","unstructured":"Javaid MK, Ward L, Pinedo-Villanueva R, Rylands AJ, Williams A, Insogna K, Imel EA (2022) Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data. J Clin Endocrinol Metab 107:e1249\u2013e1262. https:\/\/doi.org\/10.1210\/clinem\/dgab739","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/endocrines3030030","volume":"3","author":"N Ito","year":"2022","unstructured":"Ito N (2022) Adult presentation of X-linked hypophosphatemia Endocrines 3:375\u2013390. https:\/\/doi.org\/10.3390\/endocrines3030030","journal-title":"Adult presentation of X-linked hypophosphatemia Endocrines"},{"key":"2611_CR33","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1007\/s00247-022-05373-z","volume":"52","author":"RM Shore","year":"2022","unstructured":"Shore RM (2022) Disorders of phosphate homeostasis in children, part 2: hypophosphatemic and hyperphosphatemic disorders. Pediatr Radiol 52:2290\u20132305. https:\/\/doi.org\/10.1007\/s00247-022-05373-z","journal-title":"Pediatr Radiol"},{"key":"2611_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.31139\/chnriop.2022.87.2.3","volume":"87","author":"R Ganger","year":"2022","unstructured":"Ganger R, Stauffer A, Radler C, Raimann A, Kocijan R, Mindler GT (2022) X-linked hypophosphatemia. Orthopedic management in a multidisciplinary setting. Chir Narzadow Ruchu Ortop Pol 87:63\u201368. https:\/\/doi.org\/10.31139\/chnriop.2022.87.2.3","journal-title":"Chir Narzadow Ruchu Ortop Pol"},{"key":"2611_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00223-023-01172-2","volume":"114","author":"A Bosman","year":"2024","unstructured":"Bosman A, Appelman-Dijkstra NM, Boot AM, de Borst MH, van de Ven AC, de Jongh RT, B\u00f6kenkamp A, van den Bergh JP, van der Eerden BCJ, Zillikens MC (2024) Disease manifestations and complications in Dutch X-linked hypophosphatemia patients. Calcif Tissue Int 114:255\u2013266. https:\/\/doi.org\/10.1007\/s00223-023-01172-2","journal-title":"Calcif Tissue Int"},{"key":"2611_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1067\/mpd.2003.119","volume":"142","author":"C Chaussain-Miller","year":"2003","unstructured":"Chaussain-Miller C, Sinding C, Wolikow M, Lasfargues JJ, Godeau G, Garabedian M (2003) Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D. J Pediatr 142:324\u2013331. https:\/\/doi.org\/10.1067\/mpd.2003.119","journal-title":"J Pediatr"},{"key":"2611_CR37","first-page":"61","volume":"7","author":"GI Baroncelli","year":"2006","unstructured":"Baroncelli GI, Angiolini M, Ninni E, Galli V, Saggese R, Giuca MR (2006) Prevalence and pathogenesis of dental and periodontal lesions in children with X-linked hypophosphatemic rickets. Eur J Paediatr Dent 7:61\u201366 (PMID:16842025)","journal-title":"Eur J Paediatr Dent"},{"key":"2611_CR38","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0022034516677528","volume":"96","author":"M Biosse Duplan","year":"2016","unstructured":"Biosse Duplan M, Coyac BR, Bardet C, Zadikian C, Rothenbuhler A, Kamenicky P, Briot K, Linglart A, Chaussain C (2016) Phosphate and vitamin D prevent periodontitis in X-linked hypophosphatemia. J Dent Res 96:388\u2013395. https:\/\/doi.org\/10.1177\/0022034516677528","journal-title":"J Dent Res"},{"key":"2611_CR39","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.arcped.2021.09.005","volume":"28","author":"NAT Hamdy","year":"2021","unstructured":"Hamdy NAT, Harvengt P, Usardi A (2021) X-linked hypophosphatemia: The medical expert\u2019s challenges and the patient\u2019s concerns on their journey with the disease. Arch Pediatr 28:612\u2013618. https:\/\/doi.org\/10.1016\/j.arcped.2021.09.005","journal-title":"Arch Pediatr"},{"key":"2611_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41405-024-00223-6","volume":"10","author":"A Arhar","year":"2024","unstructured":"Arhar A, Pavlic A, Hocevar L (2024) Characteristics of oral health of patients with X-linked hypophosphatemia: case reports and literature review. BDJ Open 10:42. https:\/\/doi.org\/10.1038\/s41405-024-00223-6","journal-title":"BDJ Open"},{"key":"2611_CR41","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00774-020-01136-8","volume":"39","author":"GI Baroncelli","year":"2021","unstructured":"Baroncelli GI, Zampollo E, Manca M, Toschi B, Bertelloni MA, Isola A, Bulleri A et al (2021) Pulp chamber features, prevalence of abscesses, disease severity, and PHEX mutation in X-linked hypophosphatemic rickets. J Bone Miner Metab 39:212\u2013223. https:\/\/doi.org\/10.1007\/s00774-020-01136-8","journal-title":"J Bone Miner Metab"},{"key":"2611_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0307896","volume":"19","author":"R Okawa","year":"2024","unstructured":"Okawa R, Takagi M, Nakamoto T, Kakimoto N, Nakano K (2024) Evaluation of dental manifestations in X-linked hypophosphatemia using orthopantomography. PLoS ONE 19:e0307896. https:\/\/doi.org\/10.1371\/journal.pone.0307896","journal-title":"PLoS ONE"},{"key":"2611_CR43","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0564","volume":"11","author":"C Nguyen","year":"2022","unstructured":"Nguyen C, Celestin E, Chambolle D, Linglart A, Biosse Duplan M, Chaussain C, Friedlander L (2022) Oral health-related quality of life in patients with X-linked hypophosphatemia: a qualitative exploration. Endocr Connect 11:e210564. https:\/\/doi.org\/10.1530\/EC-21-0564","journal-title":"Endocr Connect"},{"key":"2611_CR44","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1017\/S0022215107001636","volume":"123","author":"G Pantel","year":"2009","unstructured":"Pantel G, Probst R, Podvinec M, Gurtler N (2009) Hearing loss and fluctuating hearing levels in X-linked hypophosphataemic osteomalacia. J Laryngol Otol 123:136\u2013140. https:\/\/doi.org\/10.1017\/S0022215107001636","journal-title":"J Laryngol Otol"},{"key":"2611_CR45","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1530\/EC-19-0481","volume":"9","author":"VV Zhukouskaya","year":"2020","unstructured":"Zhukouskaya VV, Rothenbuhler A, Colao A, Di Somma C, Kamenick\u00fd P, Trabado S, Pri\u00e9 D, Audrain C, Barosi A, Kyheng C, Lambert AS, Linglart A (2020) Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia. Endocr Connect 9:144\u2013153. https:\/\/doi.org\/10.1530\/EC-19-0481","journal-title":"Endocr Connect"},{"key":"2611_CR46","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00467-022-05636-9","volume":"38","author":"L Bloudeau","year":"2023","unstructured":"Bloudeau L, Linglart A, Flammier S, Portefaix A, Bertholet-Thomas A, Eddiry S, Barosi A, Salles JP, Porquet-Bordes V, Rothenbuhler A, Roger C, Bacchetta J (2023) XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)X-linked hypophosphatemia, obesity and arterial hypertension: data from the XLH21 study. Pediatr Nephrol 38:697\u2013704. https:\/\/doi.org\/10.1007\/s00467-022-05636-9","journal-title":"Pediatr Nephrol"},{"key":"2611_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jendso\/bvad116","volume":"7","author":"CA Simpson","year":"2023","unstructured":"Simpson CA, Santoro AM, Carpenter TO, Deng Y, Parziale S, Insogna KL (2023) Circulating levels of leptin and lipocalin-2 in patients with X-linked hypophosphatemia. J Endocr Soc 7:1\u20134. https:\/\/doi.org\/10.1210\/jendso\/bvad116","journal-title":"J Endocr Soc"},{"key":"2611_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jendso\/bvac135","volume":"6","author":"V Nguyen-Khac","year":"2022","unstructured":"Nguyen-Khac V, Bonnet-Lebrun A, Linglart A, de Tienda M, Berkenou J, Mannes I, Adamsbaum C, Wicart P, Skalli W (2022) Prospective analysis of muscle adiposity in children with X-linked hypophosphatemic rickets vs control children. J Endocr Soc 6:1\u20137. https:\/\/doi.org\/10.1210\/jendso\/bvac135","journal-title":"J Endocr Soc"},{"key":"2611_CR49","doi-asserted-by":"publisher","first-page":"1111104","DOI":"10.3389\/fendo.2023.1111104","volume":"14","author":"C Akta","year":"2023","unstructured":"Akta C, Wenzel-Schwarz F, Stauffer A, Kranzl A, Raimann A, Kocijan R, Ganger R, Mindler GT (2023) The ankle in XLH: Reduced motion, power and quality of life. Front Endocrinol 14:1111104. https:\/\/doi.org\/10.3389\/fendo.2023.1111104","journal-title":"Front Endocrinol"},{"key":"2611_CR50","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s12325-019-01193-0","volume":"37","author":"N Ferizovic","year":"2020","unstructured":"Ferizovic N, Marshall J, Williams AE, Mughal MZ, Shaw N, Mak C, Gardiner O, Hossain P, Upadhyaya S (2020) Exploring the burden of X-linked hypophosphataemia: an opportunistic qualitative study of patient statements generated during a technology appraisal. Adv Ther 37:770\u2013784. https:\/\/doi.org\/10.1007\/s12325-019-01193-0","journal-title":"Adv Ther"},{"issue":"Suppl 2","key":"2611_CR51","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13023-023-02883-3","volume":"18","author":"L Seefried","year":"2023","unstructured":"Seefried L, Alzahrani A, Sancho PA, Bacchetta J, Crowley R, Emma F, Gibbins J, Grandone A, Javaid MK, Mindler G, Raimann A, Rothenbuhler A, Tucker I, Zeitlin L, Linglart A (2023) XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH). Orphanet J Rare Dis 18(Suppl 2):333. https:\/\/doi.org\/10.1186\/s13023-023-02883-3","journal-title":"Orphanet J Rare Dis"},{"key":"2611_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13005-019-0192-x","volume":"15","author":"M Hanisch","year":"2019","unstructured":"Hanisch M, Bohner L, Sabandal MMI, Kleinheinz J, Jung S (2019) Oral symptoms and oral health-related quality of life of individuals with X-linked hypophosphatemia. Head Face Med 15:8. https:\/\/doi.org\/10.1186\/s13005-019-0192-x","journal-title":"Head Face Med"},{"key":"2611_CR53","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00005792-198911000-00002","volume":"68","author":"IR Reid","year":"1989","unstructured":"Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP (1989) X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine 68:336\u2013352 (PMID:2811660)","journal-title":"Medicine"},{"key":"2611_CR54","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1148\/radiology.171.2.2539609","volume":"71","author":"DC Hardy","year":"1989","unstructured":"Hardy DC, Murphy WA, Siegel BA, Reid IR, Whyte MP (1989) X-linked hypophosphatemia in adults: prevalence of skeletal radiografic and scintigrafic features. Radiology 71:403\u2013414. https:\/\/doi.org\/10.1148\/radiology.171.2.2539609","journal-title":"Radiology"},{"key":"2611_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-010-9373-0","volume":"87","author":"SS Beck-Nielsen","year":"2010","unstructured":"Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K, Brock-Jacobsen B, Poulsen MR, Vestergaard P, Ralston SH, Albagha OME, Poulsen S, Haubek D, Gj\u00f8rup H, Hintze H, Andersen MG, Heickendorff L, Hjelmborg J, Gram J (2010) Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int 87:108119. https:\/\/doi.org\/10.1007\/s00223-010-9373-0","journal-title":"Calcif Tissue Int"},{"key":"2611_CR56","doi-asserted-by":"publisher","first-page":"e1524","DOI":"10.1210\/clinem\/dgad383","volume":"108","author":"J Herrou","year":"2023","unstructured":"Herrou J, Fechtenbaum J, Rothenbuhler A, Kamenick\u00fd P, Roux C, Linglart A, Briot K (2023) Development of spinal enthesopathies in adults with X-linked hypophosphatemia. J Clin Endocrinol Metab 108:e1524\u2013e1531. https:\/\/doi.org\/10.1210\/clinem\/dgad383","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR57","doi-asserted-by":"publisher","first-page":"e1798","DOI":"10.1210\/clinem\/dgaa064","volume":"105","author":"A Steele","year":"2020","unstructured":"Steele A, Gonzalez R, Garbalosa JC, Steigbigel K, Grgurich T, Parisi EJ, Feinn RS, Tommasini SM, Macica CM (2020) Osteoarthritis, osteophytes, and enthesophytes affect biomechanical function in adults with X-linked hypophosphatemia. J Clin Endocrinol Metab 105:e1798\u2013e1814. https:\/\/doi.org\/10.1210\/clinem\/dgaa064","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR58","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","volume":"18","author":"A Trombetti","year":"2022","unstructured":"Trombetti A, Al-Daghri N, Brandi ML, Cannata-And\u00eda JB, Cavalier E, Chandran M, Chaussain C, Cipullo L, Cooper C, Haffner D, Harvengt P, Harvey NC et al (2022) Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nat Rev Endocrinol 18:366\u2013384. https:\/\/doi.org\/10.1038\/s41574-022-00662-x","journal-title":"Nat Rev Endocrinol"},{"key":"2611_CR59","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, Theodore-Oklota C, San Martin J (2019) The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc 3:1321\u20131334. https:\/\/doi.org\/10.1210\/js.2018-00365","journal-title":"J Endocr Soc"},{"key":"2611_CR60","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00198-022-06318-w","volume":"33","author":"G Orlando","year":"2022","unstructured":"Orlando G, Bubbear J, Clarke S, Keen R, Roy M, Anilkumar A, Schini M, Walsh JS, Javaid MK, Ireland A (2022) Physical function and physical activity in adults with X-linked hypophosphatemia. Osteop Int 33:1485\u20131491. https:\/\/doi.org\/10.1007\/s00198-022-06318-w","journal-title":"Osteop Int"},{"key":"2611_CR61","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.3390\/genes13122415","volume":"13","author":"C Romagnoli","year":"2022","unstructured":"Romagnoli C, Iantomasi T, Brandi ML (2022) Impact of X-linked hypophosphatemia on muscle symptoms. Genes 13:2415. https:\/\/doi.org\/10.3390\/genes13122415","journal-title":"Genes"},{"key":"2611_CR62","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf104","author":"M Diaz-delCastillo","year":"2025","unstructured":"Diaz-delCastillo M, Espersen RR, Beck-Nielsen SS, Rejnmark L, Heegaard AM (2025) Pain, quality of life and mental health in adults with X-linked hypophosphatemia: a cross-sectional study. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaf104","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR63","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1210\/jc.2011-1319","volume":"97","author":"EA Imel","year":"2012","unstructured":"Imel EA, Econs MJ (2012) Approach to the hypophosphatemic patient. J Clin Endocrinol Metab 97:696\u2013706. https:\/\/doi.org\/10.1210\/jc.2011-1319","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR64","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","volume":"41","author":"D Chesher","year":"2018","unstructured":"Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, Sechi A, Simister C, Waters A, Wedatilake Y, Lachmann RH, Murphy E (2018) Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 41:865\u2013876. https:\/\/doi.org\/10.1007\/s10545-018-0147-6","journal-title":"J Inherit Metab Dis"},{"key":"2611_CR65","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae185","author":"EA Imel","year":"2024","unstructured":"Imel EA, Li Z, Heerssen HM, Princic N, Schwartz H, Zhao Y, Dahir KM (2024) Real-world clinical and healthcare resource burden among burosumab-na\u00efve patients with familial hypophosphatemia. J Endocr Soc. https:\/\/doi.org\/10.1210\/jendso\/bvae185","journal-title":"J Endocr Soc"},{"key":"2611_CR66","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0221-8747(82)90035-2","volume":"4","author":"PJ Marie","year":"1982","unstructured":"Marie PJ, Glorieux FH (1982) Bone histomorphometry in asyntomatic adults with hereditary hypophosphatemic vitamin D-resistant osteomalacia. Metab Bone Dis Rel Res 4:249\u2013253. https:\/\/doi.org\/10.1016\/0221-8747(82)90035-2","journal-title":"Metab Bone Dis Rel Res"},{"key":"2611_CR67","doi-asserted-by":"publisher","first-page":"1087761","DOI":"10.3389\/froh.2023.1087761","volume":"4","author":"A Larsson","year":"2023","unstructured":"Larsson A, Regnstrand T, Skott P, M\u00e4kitie O, Bj\u00f6rnsdottir S, Garming-Legert K (2023) Dental health of patients with X-linked hypophosphatemia: a controlled study. Front Oral Health 4:1087761. https:\/\/doi.org\/10.3389\/froh.2023.1087761","journal-title":"Front Oral Health"},{"key":"2611_CR68","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12903-024-04028-9","volume":"24","author":"J Steur","year":"2024","unstructured":"Steur J, Bohner L, Jackowski J, Hanisch M, Oelerich O (2024) Oral health and oral-health-related quality of life in people with X-linked hypophosphatemia. BMC Oral Health 24:259. https:\/\/doi.org\/10.1186\/s12903-024-04028-9","journal-title":"BMC Oral Health"},{"key":"2611_CR69","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1210\/JC.2015-2199","volume":"100","author":"J Connor","year":"2015","unstructured":"Connor J, Olear EA, Insogna KL, Katz L, Baker S, Kaur R, Simpson CA, Sterpka J, Dubrov R, Zhang JH, Carpenter TO (2015) Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease. J Clin Endocrinol Metab 100:3625\u20133632. https:\/\/doi.org\/10.1210\/JC.2015-2199","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR70","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae398","author":"A Herv\u00e9","year":"2024","unstructured":"Herv\u00e9 A, Gadion M, Herrou J, Izart M, Linglart A, Cohen-Solal M, Lecoq AL, Kamenicky P, Briot K, Chaussain C, Duplan MB (2024) Improved oral health in adults with X-linked hypophosphatemia treated with burosumab. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae398","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR71","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1210\/jcem.82.8.4181","volume":"82","author":"R Nehgme","year":"1997","unstructured":"Nehgme R, Fahey JT, Smith C, Carpenter TO (1997) Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 82:2450\u20132454. https:\/\/doi.org\/10.1210\/jcem.82.8.4181","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR72","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1507\/endocrj.EJ16-0199","volume":"64","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Takagi M, Takeda R, Miyai K, Hasegawa Y (2017) Hypertension is a characteristic complication of X-linked hypophosphatemia. Endocr J 64:283\u2013289. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0199","journal-title":"Endocr J"},{"key":"2611_CR73","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/07435800.2016.1242604","volume":"42","author":"Y Takashi","year":"2017","unstructured":"Takashi Y, Yuka Kinoshita Y, Hori M, Ito N, Taguchi M, Fukumoto S (2017) Patients with FGF23-related hypophosphatemic rickets\/osteomalacia do not present with left ventricular hypertrophy. Endocr Res 42:132\u2013137. https:\/\/doi.org\/10.1080\/07435800.2016.1242604","journal-title":"Endocr Res"},{"key":"2611_CR74","doi-asserted-by":"publisher","first-page":"e488","DOI":"10.1210\/clinem\/dgad608","volume":"109","author":"A Bouzemane","year":"2024","unstructured":"Bouzemane A, Vignot E, Derain Dubourg L, De Mul A, Molin A, Chapurlat R, Fontanges E, Delsart D, Akbari A, Huang SHS, McIntyre CW, Bacchetta J, Lemoine S (2024) Reassuring data on the cardiovascular risk in adults with X-linked hypophosphatemia receiving conventional therapy. J Clin Endocrinol Metab 109:e488\u2013e494. https:\/\/doi.org\/10.1210\/clinem\/dgad608","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR75","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/ejendo\/lvae089","volume":"191","author":"AL Lecoq","year":"2024","unstructured":"Lecoq AL, Schilbach K, Rocher L, Trabado S, Briot K, Herrou J, Forbes A, Garnier A, Piketty M, Bidlingmaier M, Rothenbuhler A, Linglart A, Carette C, Chaumet-Riffaud P, Kamenick\u00fd P (2024) Metabolically healthy obesity in adults with X-linked hypophosphatemia. Eur J Endocrinol 191:156\u2013165. https:\/\/doi.org\/10.1093\/ejendo\/lvae089","journal-title":"Eur J Endocrinol"},{"key":"2611_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-011-0340-2","volume":"30","author":"TO Carpenter","year":"2012","unstructured":"Carpenter TO (2012) The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 30:1\u20139. https:\/\/doi.org\/10.1007\/s00774-011-0340-2","journal-title":"J Bone Miner Metab"},{"key":"2611_CR77","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00005792-195805000-0000","volume":"37","author":"RW Winters","year":"1958","unstructured":"Winters RW, Graham JB, Williams TF, McFalls VW, Burnett CH (1958) A genetic study of familial hypophosphatemia and vitamin D resistant rickets with a review of the literature. Medicine 37:97\u2013142. https:\/\/doi.org\/10.1097\/00005792-195805000-0000","journal-title":"Medicine"},{"key":"2611_CR78","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/jbmr.5650070602","volume":"7","author":"DJ Petersen","year":"1992","unstructured":"Petersen DJ, Boniface AM, Schranck FW, Rupich RC, Whyte MP (1992) X-linked hypophosphatemic rickets: a study (with literature review) of linear growth response to calcitriol and phosphate therapy. J Bone Miner Res 7:583\u2013597. https:\/\/doi.org\/10.1002\/jbmr.5650070602","journal-title":"J Bone Miner Res"},{"key":"2611_CR79","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1373\/clinchem.2011.177741","volume":"58","author":"DA Colantonio","year":"2012","unstructured":"Colantonio DA, Kyriakopoulou L, Chan MK, Daly CH, Brinc D, Venner AA, Pasic MD, Armbruster D, Adeli K (2012) Closing the gaps in pediatric laboratory reference intervals: a caliper database of 40 biochemical markers in a healthy and multiethnic population of children. Clin Chem 58:854\u2013868. https:\/\/doi.org\/10.1373\/clinchem.2011.177741","journal-title":"Clin Chem"},{"key":"2611_CR80","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s40618-023-02202-4","volume":"47","author":"GI Baroncelli","year":"2024","unstructured":"Baroncelli GI, Sessa MR, Pelosini C, Bertelloni S, Michelucci A, Toschi B, Piaggi P, Peroni D, Comberiati P (2024) Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X-linked hypophosphatemic rickets. J Endocrinol Invest 47:873\u2013882. https:\/\/doi.org\/10.1007\/s40618-023-02202-4","journal-title":"J Endocrinol Invest"},{"key":"2611_CR81","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1210\/clinem\/dgad597","volume":"109","author":"V Pott","year":"2024","unstructured":"Pott V, Tietze H, Kanzelmeyer N, von der Born J, Baumann U, Mindermann C, Suhlrie A, Drube J, Melk A, Das AM, Schnabel D, Haffner D, Leifheit-Nestler M (2024) LMS-based pediatric reference values for parameters of phosphate homeostasis in the harp cohort. J Clin Endocrinol Metab 109:668\u2013679. https:\/\/doi.org\/10.1210\/clinem\/dgad597","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR82","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000184216","volume":"44","author":"H Stark","year":"1986","unstructured":"Stark H, Eisenstein B, Tieder M, Rachmel A, Alpert G (1986) Direct measurement of TP\/GFR: a simple and reliable parameter of renal phosphate handling. Nephron 44:125\u2013128. https:\/\/doi.org\/10.1159\/000184216","journal-title":"Nephron"},{"key":"2611_CR83","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF00862587","volume":"2","author":"J Brodehl","year":"1988","unstructured":"Brodehl J, Krause A, Hoyer PF (1988) Assessment of maximal tubular phosphate reabsorption: comparison of direct measure- ment with the nomogram of Bijvoet. Pediatr Nephrol 2:183\u2013189. https:\/\/doi.org\/10.1007\/BF00862587","journal-title":"Pediatr Nephrol"},{"key":"2611_CR84","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0140-6736(75)92736-1","volume":"2","author":"RJ Walton","year":"1975","unstructured":"Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309\u2013310. https:\/\/doi.org\/10.1016\/s0140-6736(75)92736-1","journal-title":"Lancet"},{"key":"2611_CR85","doi-asserted-by":"publisher","first-page":"1383681","DOI":"10.3389\/fendo.2024.1383681","volume":"15","author":"GI Baroncelli","year":"2024","unstructured":"Baroncelli GI, Comberiati P, Aversa T, Baronio F, Cassio A, Chiarito M, Cosci M, De Sanctis L, Di Iorgi N, Faienza MF, Fintini D, Franceschi R et al (2024) Diagnosis, treatment, and management of rickets: a position statement from the Bone and Mineral Metabolism Group of the Italian Society of Pediatric Endocrinology and Diabetology. Front Endocrinol 15:1383681. https:\/\/doi.org\/10.3389\/fendo.2024.1383681","journal-title":"Front Endocrinol"},{"key":"2611_CR86","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/080352500750027763","volume":"89","author":"GI Baroncelli","year":"2000","unstructured":"Baroncelli GI, Bertelloni S, Ceccarelli C, Amato V, Saggese G (2000) Bone turnover in children with vitamin D deficiency rickets before and during treatment. Acta Paediatr 89:513\u2013518. https:\/\/doi.org\/10.1080\/080352500750027763","journal-title":"Acta Paediatr"},{"key":"2611_CR87","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.15231755.2001.00794.x","volume":"60","author":"P Magnusson","year":"2001","unstructured":"Magnusson P, Sharp CA, Magnusson M, Risteli J, Davie MWJ, Larsson L (2001) Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 60:257\u2013265. https:\/\/doi.org\/10.1046\/j.15231755.2001.00794.x","journal-title":"Kidney Int"},{"key":"2611_CR88","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381\u20131388. https:\/\/doi.org\/10.1002\/jbmr.340","journal-title":"J Bone Miner Res"},{"key":"2611_CR89","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, Hogler W, Linglart A, Padidela R, Portale AA (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378:1987\u20131998. https:\/\/doi.org\/10.1056\/NEJMoa1714641","journal-title":"N Engl J Med"},{"key":"2611_CR90","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1210\/jcem.75.3.1517380","volume":"75","author":"W Sullivan","year":"1992","unstructured":"Sullivan W, Carpenter TO, Glorieux FH, Travers R, Insogna K (1992) A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 75:879\u2013885. https:\/\/doi.org\/10.1210\/jcem.75.3.1517380","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR91","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00223-019-00526-z","volume":"104","author":"S Hansen","year":"2019","unstructured":"Hansen S, Shanbhogue VV, J\u00f8rgensen NR, Beck-Nielsen SS (2019) Elevated bone remodeling markers of CTX and P1NP in addition to sclerostin in patients with X-linked hypophosphatemia: a cross-sectional controlled study. Calcif Tissue Int 104:591\u2013598. https:\/\/doi.org\/10.1007\/s00223-019-00526-z","journal-title":"Calcif Tissue Int"},{"key":"2611_CR92","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/jbmr.3992","volume":"35","author":"AL Lecoq","year":"2020","unstructured":"Lecoq AL, Chaumet-Riffaud P, Blanchard A, Dupeux M, Rothenbuhler A, Lambert B, Durand E, Boros E, Briot K, Silve C, Francou B, Piketty M, Chanson P, Brailly-Tabard S, Linglart A, Kamenick\u00fd P (2020) Hyperparathyroidism in patients with X-linked hypophosphatemia. J Bone Miner Res 35:1263\u20131273. https:\/\/doi.org\/10.1002\/jbmr.3992","journal-title":"J Bone Miner Res"},{"key":"2611_CR93","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1681\/ASN.V11101865","volume":"11","author":"A Canalejo","year":"2000","unstructured":"Canalejo A, Almad\u00e9n Y, Torregrosa V, Gomez-Villamandos J, Ramos B, Campistol JM, Felsenfeld AJ, Rodr\u00edguez M (2000) The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis. J Am Soc Nephrol 11:1865\u20131872. https:\/\/doi.org\/10.1681\/ASN.V11101865","journal-title":"J Am Soc Nephrol"},{"key":"2611_CR94","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s004670050669","volume":"13","author":"TD Blydt-Hansen","year":"1999","unstructured":"Blydt-Hansen TD, Tenenhouse HS, Goodyer P (1999) PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Pediatr Nephrol 13:607\u2013611. https:\/\/doi.org\/10.1007\/s004670050669","journal-title":"Pediatr Nephrol"},{"key":"2611_CR95","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1056\/NEJM197811022991803","volume":"299","author":"CR Scriver","year":"1978","unstructured":"Scriver CR, Reade TM, DeLuca HF, Hamstra AJ (1978) Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets of bone disease. N Engl J Med 299:976\u2013979. https:\/\/doi.org\/10.1056\/NEJM197811022991803","journal-title":"N Engl J Med"},{"key":"2611_CR96","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/BF02411222","volume":"34","author":"KW Lyles","year":"1982","unstructured":"Lyles KW, Clark AG, Drezner MK (1982) Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalacia. Calcif Tissue Int 34:125\u2013130. https:\/\/doi.org\/10.1007\/BF02411222","journal-title":"Calcif Tissue Int"},{"key":"2611_CR97","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1172\/jci110912","volume":"71","author":"KL Insogna","year":"1983","unstructured":"Insogna KL, Broadus AE, Gertner JM (1983) Impaired phosphorus conservation and 1,25 dihydroxyvitamin D generation during phosphorus deprivation in familial hypophosphatemic rickets. J Clin Invest 71:1562\u20131569. https:\/\/doi.org\/10.1172\/jci110912","journal-title":"J Clin Invest"},{"key":"2611_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10558","volume":"5","author":"N Latic","year":"2021","unstructured":"Latic N, Erben RG (2021) FGF23 and vitamin D metabolism. JBMR Plus 5:e10558. https:\/\/doi.org\/10.1002\/jbm4.10558","journal-title":"JBMR Plus"},{"key":"2611_CR99","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40618-019-01165-9","volume":"43","author":"R Indirli","year":"2020","unstructured":"Indirli R, Guabello G, Longhi M, Niada S, Maruca K, Mora S, Maggioni M, Corbetta S (2020) FGF23-related hypophosphatemia in patients with low bone mineral density and fragility fractures: challenges in diagnosis and management. J Endocrinol Invest 43:787\u2013798. https:\/\/doi.org\/10.1007\/s40618-019-01165-9","journal-title":"J Endocrinol Invest"},{"key":"2611_CR100","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","volume":"42","author":"I Endo","year":"2008","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients. Proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235\u20131239. https:\/\/doi.org\/10.1016\/j.bone.2008.02.014","journal-title":"Bone"},{"key":"2611_CR101","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00774-021-01258-7","volume":"40","author":"H Kato","year":"2022","unstructured":"Kato H, Hidaka N, Koga M, Ogawa N, Takahashi S, Miyazaki H, Nangaku M, Makita N, Ito N (2022) Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system. J Bone Miner Metab 40:101\u2013108. https:\/\/doi.org\/10.1007\/s00774-021-01258-7","journal-title":"J Bone Miner Metab"},{"key":"2611_CR102","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/jbmr.4702","volume":"37","author":"IR Hartley","year":"2022","unstructured":"Hartley IR, Gafni RI, Roszko KL, Brown SM, de Castro LF, Saikali A, Ferreira CR, Gahl WA, Pacak K, Blau JE, Boyce AM, Salusky IB, Collins MT, Florenzano P (2022) Determination of FGF23 levels for the diagnosis of FGF23-mediated hypophosphatemia. J Bone Miner Res 37:2174\u20132185. https:\/\/doi.org\/10.1002\/jbmr.4702","journal-title":"J Bone Miner Res"},{"key":"2611_CR103","first-page":"529","volume":"54","author":"F Albright","year":"1937","unstructured":"Albright F, Butler AM, Bloomberg E (1937) Rickets resistant to vitamin D therapy. Am J Disab Child 54:529\u2013547","journal-title":"Am J Disab Child"},{"key":"2611_CR104","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/B978-0-12-382040-2.10026-7","volume-title":"Pediatric bone: biology and diseases","author":"IA Holm","year":"2012","unstructured":"Holm IA, Econs MJ, Carpenter TO (2012) Familial hypophosphatemia and related disorders. In: Glorieux FH, Pettifor JM, Juppne H (eds) Pediatric bone: biology and diseases, 2nd edn. Academic Press, London, pp 699\u2013726","edition":"2"},{"key":"2611_CR105","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13052-019-0654-6","volume":"45","author":"F Emma","year":"2019","unstructured":"Emma F, Cappa M, Antoniazzi F, Bianchi ML, Chiodini I, Eller Vainicher C, Di Iorgi N, Maghnie M, Cassio A, Balsamo A, Baronio F, De Sanctis L, Tessaris D, Baroncelli GI, Mora S, Brandi ML, Weber G, D\u2019Ausilio A, Lanati EP (2019) X-linked hypophosphatemic rickets: an Italian experts\u2019 opinion survey. It J Pediatr 45:67. https:\/\/doi.org\/10.1186\/s13052-019-0654-6","journal-title":"It J Pediatr"},{"key":"2611_CR106","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00223-017-0363-3","volume":"102","author":"VV Shanbhogue","year":"2018","unstructured":"Shanbhogue VV, Hansen S, J\u00f8rgensen NR, Beck-Nielsen SS (2018) Impact of conventional medical therapy on bone mineral density and bone turnover in adult patients with X-linked hypophosphatemia: a 6-year prospective cohort study. Calcif Tissue Int 102:321\u2013328. https:\/\/doi.org\/10.1007\/s00223-017-0363-3","journal-title":"Calcif Tissue Int"},{"key":"2611_CR107","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s11136-020-02465-x","volume":"29","author":"SH Lo","year":"2020","unstructured":"Lo SH, Lachmann R, Williams A, Piglowska N, Lloyd AJ (2020) Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. Qual Life Res 29:1883\u20131893. https:\/\/doi.org\/10.1007\/s11136-020-02465-x","journal-title":"Qual Life Res"},{"key":"2611_CR108","first-page":"361","volume":"1","author":"GI Baroncelli","year":"2004","unstructured":"Baroncelli GI, Bertelloni S, Sodini F, Galli L, Vanacore T, Fiore L, Saggese G (2004) Genetic advances, biochemical and clinical features and critical approach to treatment of patients with X-linked hypophosphatemic rickets. Pediatr Endocrinol Rev 1:361\u2013379 (PMID:16437029)","journal-title":"Pediatr Endocrinol Rev"},{"key":"2611_CR109","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJM197209072871003","volume":"287","author":"FH Glorieux","year":"1972","unstructured":"Glorieux FH, Scriver CR, Reade TM, Goldman H, Roseborough A (1972) Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia. N Engl J Med 287:481\u2013487. https:\/\/doi.org\/10.1056\/NEJM197209072871003","journal-title":"N Engl J Med"},{"key":"2611_CR110","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1210\/jcem-52-3-463","volume":"52","author":"T Costa","year":"1981","unstructured":"Costa T, Marie PJ, Scriver CR, Cole DED, Reade TM, Nogrady B, Glorieux FH, Delvin EE (1981) X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J Clin Endocrinol Metab 52:463\u2013472. https:\/\/doi.org\/10.1210\/jcem-52-3-463","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR111","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00442454","volume":"142","author":"Y Seino","year":"1984","unstructured":"Seino Y, Satomura K, Yamaoka K, Tanaka Y, Yamamoto T, Ishida M, Yabuuchi H (1984) Activity or renal 25-hydroxyvitamin D3\u20131\u03b1-hydroxylase in a case of X-linked hypophosphatemic rickets. Eur J Pediatr 142:219\u2013222. https:\/\/doi.org\/10.1007\/BF00442454","journal-title":"Eur J Pediatr"},{"key":"2611_CR112","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00467-019-04290-y","volume":"35","author":"ME Robinson","year":"2019","unstructured":"Robinson ME, AlQuorain H, Murshed M, Rauch F (2019) Mineralized tissues in hypophosphatemic rickets. Pediatr Nephrol 35:1843\u20131854. https:\/\/doi.org\/10.1007\/s00467-019-04290-y","journal-title":"Pediatr Nephrol"},{"key":"2611_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002427","volume":"14","author":"SK Murali","year":"2016","unstructured":"Murali SK, Andrukhova O, Clinkenbeard EL, White KE, Erben RG (2016) Excessive osteocytic FGF23 secretion contributes to pyrophosphate accumulation and mineralization defect in Hyp mice. PLoS Biol 14:e1002427. https:\/\/doi.org\/10.1371\/journal.pbio.1002427","journal-title":"PLoS Biol"},{"key":"2611_CR114","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bone.2016.11.019","volume":"95","author":"T Boukpessi","year":"2017","unstructured":"Boukpessi T, Hoac B, Coyac BR, Leger T, Garcia C, Wicart P, Whyte MP, Glorieux FH, Linglart A, Chaussain C, McKee MD (2017) Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. Bone 95:151\u2013161. https:\/\/doi.org\/10.1016\/j.bone.2016.11.019","journal-title":"Bone"},{"key":"2611_CR115","first-page":"A4874","volume":"61","author":"LH Nielsen","year":"2014","unstructured":"Nielsen1 LH, Rahbek ET, Beck\u00adNielsen SS, Christesen HT, (2014) Treatment of hypophosphataemic rickets in children remains a challenge. Dan Med J 61:A4874 (PMID:25123121)","journal-title":"Dan Med J"},{"key":"2611_CR116","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.arcped.2021.09.003","volume":"28","author":"F Di Rocco","year":"2021","unstructured":"Di Rocco F, Rothenbuhler A, Adamsbaumd C, Bacchetta J, Pejin Z, Finidori G, Pannier S, Linglart L, Wicart P (2021) Orthopedic and neurosurgical care of X-linked hypophosphatemia. Arch Pediatr 28:599\u2013605. https:\/\/doi.org\/10.1016\/j.arcped.2021.09.003","journal-title":"Arch Pediatr"},{"key":"2611_CR117","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/endocrines3030039","volume":"3","author":"C Higuchi","year":"2022","unstructured":"Higuchi C (2022) Orthopedic complications and management in children with X-linked hypophosphatemia. Endocrines 3:488\u2013497. https:\/\/doi.org\/10.3390\/endocrines3030039","journal-title":"Endocrines"},{"key":"2611_CR118","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2106\/00004623-198062070-00010","volume":"62","author":"GA Evans","year":"1980","unstructured":"Evans GA, Arulanantham K, Gage JR (1980) Primary hypophosphatemic rickets. Effect of oral phosphate and vitamin D on growth and surgical treatment. J Bone Joint Surg Am 62:1130\u20131138 (PMID:6253500)","journal-title":"J Bone Joint Surg Am"},{"key":"2611_CR119","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1302\/18632548.11.170003","volume":"11","author":"A Horn","year":"2017","unstructured":"Horn A, Wright J, Bockenhauer D, Van\u2019t Hoff W, Eastwood DM, (2017) The orthopaedic management of lower limb deformity in hypophosphataemic rickets. J Child Orthop 11:298\u2013305. https:\/\/doi.org\/10.1302\/18632548.11.170003","journal-title":"J Child Orthop"},{"key":"2611_CR120","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1007\/s11999-008-0547-2","volume":"466","author":"G Petje","year":"2008","unstructured":"Petje G, Meizer R, Radler C, Aigner N, Grill F (2008) Deformity correction in children with hereditary hypophosphatemic rickets. Clin Orthop Relat Res 466:3078\u20133085. https:\/\/doi.org\/10.1007\/s11999-008-0547-2","journal-title":"Clin Orthop Relat Res"},{"key":"2611_CR121","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1210\/jc.2003-030036","volume":"88","author":"O Makitie","year":"2003","unstructured":"Makitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E (2003) Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 88:3591\u20133597. https:\/\/doi.org\/10.1210\/jc.2003-030036","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgaa495","volume":"105","author":"M Mao","year":"2020","unstructured":"Mao M, Carpenter TO, Whyte MP, Skrinar A, Chen CY, San Martin J, Rogol AD (2020) Growth curves for children with X-linked hypophosphatemia. J Clin Endocrinol Metab 105:1\u20137. https:\/\/doi.org\/10.1210\/clinem\/dgaa495","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR123","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1074\/jbc.M112.410043","volume":"288","author":"M Kawai","year":"2013","unstructured":"Kawai M, Kinoshita S, Kimoto A, Hasegawa Y, Miyagawa K, Yamazaki M, Ohata Y, Ozono K, Michigani T (2013) FGF23 suppresses chondrocyte proliferation in the presence of soluble \u03b1-klotho both in vitro and in vivo. J Biol Chem 288:2414\u20132427. https:\/\/doi.org\/10.1074\/jbc.M112.410043","journal-title":"J Biol Chem"},{"key":"2611_CR124","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/s0140-6736(89)91559-6","volume":"2","author":"GB Stickler","year":"1989","unstructured":"Stickler GB, Morgenstern BZ (1989) Hypophosphatemic rickets. final height and clinical symptoms in adults. Lancet 2:902\u2013905. https:\/\/doi.org\/10.1016\/s0140-6736(89)91559-6","journal-title":"Lancet"},{"key":"2611_CR125","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1210\/jcem.76.4.8473393","volume":"76","author":"NE Friedman","year":"1993","unstructured":"Friedman NE, Lobaugh B, Drezner MK (1993) Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 76:839\u2013844. https:\/\/doi.org\/10.1210\/jcem.76.4.8473393","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR126","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00467-010-1705-9","volume":"26","author":"\u017divi\u010dnjak M, Schnabel D, Billing H, Staude H, Filler G, Querfeld U, Schumacher M, Pyper A, Schr\u00f6der C, Br\u00e4mswig J, Haffner D; Hypophosphatemic Rickets Study Group of Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Endokrinologie and Gesellschaft f\u00fcr P\u00e4diatrische Nephrologie","year":"2011","unstructured":"\u017divi\u010dnjak M, Schnabel D, Billing H, Staude H, Filler G, Querfeld U, Schumacher M, Pyper A, Schr\u00f6der C, Br\u00e4mswig J, Haffner D; Hypophosphatemic Rickets Study Group of Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Endokrinologie and Gesellschaft f\u00fcr P\u00e4diatrische Nephrologie (2011) Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol 26:223\u2013231. https:\/\/doi.org\/10.1007\/s00467-010-1705-9","journal-title":"Pediatr Nephrol"},{"issue":"Suppl 1","key":"2611_CR127","doi-asserted-by":"publisher","first-page":"119","DOI":"10.17458\/per.vol15.2017.crb.spontaneousgrowtheffect","volume":"15","author":"M Cagnoli","year":"2017","unstructured":"Cagnoli M, Richter R, B\u00f6hm P, Knye K, Empting S, Mohnike K (2017) Spontaneous growth and effect of early therapy with calcitriol and phosphate in X-linked hypophosphatemic rickets. Pediatr Endocrinol Rev 15(Suppl 1):119\u2013122. https:\/\/doi.org\/10.17458\/per.vol15.2017.crb.spontaneousgrowtheffect","journal-title":"Pediatr Endocrinol Rev"},{"key":"2611_CR128","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40618-022-01768-9","volume":"45","author":"M del Pino","year":"2022","unstructured":"del Pino M, Viterbo GL, Arenas MA, Perez Garrido N, Ramirez P, Marino R, Belgorosky A, Fano V (2022) Growth in height and body proportion from birth to adulthood in hereditary hypophosphatemic rickets: a retrospective cohort study. J Endocrinol Invest 45:1349\u20131358. https:\/\/doi.org\/10.1007\/s40618-022-01768-9","journal-title":"J Endocrinol Invest"},{"key":"2611_CR129","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/ejendo\/lvad144","volume":"189","author":"E Boros","year":"2023","unstructured":"Boros E, Ertl DA, Berkenou J, Audrain C, Lecoq AL, Kamenicky P, Briot K, Amouroux C, Zhukouskaya V, Gueorguieva I, Mignot B, Girerd B (2023) Adult height improved over decades in patients with X-linked hypophosphatemia: a cohort study. Eur J Endocrinol 189:469\u2013475. https:\/\/doi.org\/10.1093\/ejendo\/lvad144","journal-title":"Eur J Endocrinol"},{"key":"2611_CR130","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1067\/mpd.2001.108955","volume":"138","author":"GI Baroncelli","year":"1991","unstructured":"Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G (1991) Effect of growth hormone treatment on final height, phosphate metabolism and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 138:236\u2013243. https:\/\/doi.org\/10.1067\/mpd.2001.108955","journal-title":"J Pediatr"},{"key":"2611_CR131","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.6.e593","volume":"113","author":"D Haffner","year":"2004","unstructured":"Haffner D, Nissel R, W\u00fchl E, Mehls O (2004) Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics 113:e593. https:\/\/doi.org\/10.1542\/peds.113.6.e593","journal-title":"Pediatrics"},{"key":"2611_CR132","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00467-017-3820-3","volume":"33","author":"N Meyerhoff","year":"2018","unstructured":"Meyerhoff N, Haffner D, Staude H, W\u00fchl E, Marx M, Beetz R, Querfeld U, Holder M, Billing H, Rabl W, Schr\u00f6der C, Hiort O et al (2018) Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets. Pediatr Nephrol 33:447\u2013456. https:\/\/doi.org\/10.1007\/s00467-017-3820-3","journal-title":"Pediatr Nephrol"},{"key":"2611_CR133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004447.pub3","author":"S Smith","year":"2021","unstructured":"Smith S, Remmington T (2021) Recombinant growth hormone therapy for X-linked hypophosphatemia in children (Review). Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD004447.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"2611_CR134","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s13023-022-02590-5","volume":"17","author":"J Andr\u00e9","year":"2022","unstructured":"Andr\u00e9 J, Zhukouskaya VV, Lambert AS, Salles JP, Mignot B, Bardet C, Chaussain C, Rothenbuhler A, Linglart A (2022) Growth hormone treatment improves final height in children with X-linked hypophosphatemia. Orphanet J Rare Dis 17:444. https:\/\/doi.org\/10.1186\/s13023-022-02590-5","journal-title":"Orphanet J Rare Dis"},{"key":"2611_CR135","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000113021","volume":"69","author":"O Makitie","year":"2008","unstructured":"Makitie O, Toiviainen-Salo S, Marttinen E, Kaitila I, Sochett E, Sipila I (2008) Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets. Horm Res 69:212\u2013220. https:\/\/doi.org\/10.1159\/000113021","journal-title":"Horm Res"},{"key":"2611_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM198507043130101","volume":"313","author":"R Polisson","year":"1985","unstructured":"Polisson R, Martinez S, Khoury M, Harrel RM, Lyles KW, Friedman N, Harrelson JM, Reisner E, Drezner MK (1985) Calcification of entheses associated with X-linked hypophosphatenic osteomalacia. N Engl J Med 313:1\u20136. https:\/\/doi.org\/10.1056\/NEJM198507043130101","journal-title":"N Engl J Med"},{"key":"2611_CR137","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","volume":"17","author":"MIL Yanes","year":"2022","unstructured":"Yanes MIL, Diaz-Curiel M, Peris P, Vicente C, Marin S, Ramon-Krauel M, Hernandez J, Broseta JJ, Espinosa L, Mendizabal S, Perez-Sukia L, Mart\u00ednez V, Palaz\u00f3n C, Pi\u00f1ero JA, Calleja MA, Espin J, Arborio-Pinel R, Ariceta G (2022) Health-related quality of life of X-linked hypophosphatemia in Spain. Orphanet J Rare Dis 17:298. https:\/\/doi.org\/10.1186\/s13023-022-02452-0","journal-title":"Orphanet J Rare Dis"},{"key":"2611_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2024.104958","volume":"70","author":"GI Baroncelli","year":"2024","unstructured":"Baroncelli GI, Grandone A, Aversa A, Sessa MR, Pelosini C, Michelucci A, Toschi B, Manca M, Isola A, Comberiati P (2024) Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets. Eur J Med Genet 70:104958. https:\/\/doi.org\/10.1016\/j.ejmg.2024.104958","journal-title":"Eur J Med Genet"},{"key":"2611_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2024.104912","volume":"68","author":"E Wagner","year":"2024","unstructured":"Wagner E, Bertholet-Thomas A, Romiera M, Loin L, Lemoine S, Vignot E, Flammier S, Garnier C, De-Mul A, Feutrier C, Juillard S, Thivichon-Prince B, Lienhart G, Bacchetta J (2024) X-linked hypophosphatemia: the value of feedback focus groups to assess patient and caregiver needs. Eur J Med Genet 68:104912. https:\/\/doi.org\/10.1016\/j.ejmg.2024.104912","journal-title":"Eur J Med Genet"},{"key":"2611_CR140","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1601-0825.2006.01326.x","volume":"13","author":"C Chaussain-Miller","year":"2007","unstructured":"Chaussain-Miller C, Sinding C, Septier D, Wolikow M, Goldberg M, Garabedian M (2007) Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. Oral Dis 13:482\u2013489. https:\/\/doi.org\/10.1111\/j.1601-0825.2006.01326.x","journal-title":"Oral Dis"},{"key":"2611_CR141","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1210\/jcem.78.6.8200940","volume":"78","author":"TO Carpenter","year":"1994","unstructured":"Carpenter TO, Mitnick MA, Ellison A, Smith C, Insogna KL (1994) Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab 78:1378\u20131383. https:\/\/doi.org\/10.1210\/jcem.78.6.8200940","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR142","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2265.2003.01685.x","volume":"58","author":"O M\u00e4kitie","year":"2003","unstructured":"M\u00e4kitie O, Kooh SW, Sochett E (2003) Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol 58:163\u2013168. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01685.x","journal-title":"Clin Endocrinol"},{"key":"2611_CR143","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bone.2019.06.025","volume":"127","author":"S DeLacey","year":"2019","unstructured":"DeLacey S, Liu Z, Broyles A, El-Azab SA, Guandique CF, James BC, Imel EA (2019) Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. Bone 127:386\u2013392. https:\/\/doi.org\/10.1016\/j.bone.2019.06.025","journal-title":"Bone"},{"key":"2611_CR144","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","volume":"325","author":"CF Verge","year":"1991","unstructured":"Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M (1991) Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325:1843\u20131848. https:\/\/doi.org\/10.1056\/NEJM199112263252604","journal-title":"N Engl J Med"},{"key":"2611_CR145","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/jbmr\/zjae127","volume":"39","author":"AA Portale","year":"2024","unstructured":"Portale AA, Ward L, Dahir K, Florenzano P, Ing SW, Jan de Beur SMJ, Martin RM, Meza-Martinez AI, Paloian N, Ashraf A, Dixon BP, Khan A, Langman C, Chen A, Wang C, Roberts MS, Tandon PK, Bedrosian C, Imel EA (2024) Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study. J Bone Miner Res 39:1493\u20131502. https:\/\/doi.org\/10.1093\/jbmr\/zjae127","journal-title":"J Bone Miner Res"},{"key":"2611_CR146","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1210\/js.2018-00338","volume":"3","author":"GP Colares Neto","year":"2019","unstructured":"Colares Neto GP, Ide Yamauchi F, Hueb Baroni R, de Andrade BM, Cavalanti Gomes A, Chammas MC, Matsunaga Martin R (2019) Nephrocalcinosis and nephrolithiasis in X-linked hypophosphatemic rickets: diagnostic imaging and risk factors. J Endocr Soc 3:1053\u20131061. https:\/\/doi.org\/10.1210\/js.2018-00338","journal-title":"J Endocr Soc"},{"key":"2611_CR147","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00467-002-1044-6","volume":"18","author":"US Alon","year":"2003","unstructured":"Alon US, Monzavi R, Lilien M, Rasoulpour M, Geffner ME, Yadin, (2003) Hypertension in hypophosphatemic rickets: role of secondary hyperparathyroidism. Pediatr Nephrol 18:155\u2013158. https:\/\/doi.org\/10.1007\/s00467-002-1044-6","journal-title":"Pediatr Nephrol"},{"key":"2611_CR148","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1530\/EC-20-0291","volume":"9","author":"R Padidela","year":"2020","unstructured":"Padidela R, Cheung MS, Saraff V, Dharmaraj P (2020) Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations. Endocr Connect 9:1051\u20131056. https:\/\/doi.org\/10.1530\/EC-20-0291","journal-title":"Endocr Connect"},{"key":"2611_CR149","doi-asserted-by":"publisher","first-page":"1034580","DOI":"10.3389\/fendo.2022.1034580","volume":"13","author":"MZ Mughal","year":"2023","unstructured":"Mughal MZ, Baroncelli GI, de Lucas-Collantes C, Linglart A, Magnolato A, Raimann A, Santos F, Schnabel D, Shaw N, Nilsson O (2023) Burosumab for X-linked hypophosphatemia in children and adolescents: opinion based on early experience in seven European countries. Front Endocrinol 13:1034580. https:\/\/doi.org\/10.3389\/fendo.2022.1034580","journal-title":"Front Endocrinol"},{"key":"2611_CR150","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1210\/clinem\/dgac488","volume":"108","author":"SA Ackah","year":"2023","unstructured":"Ackah SA, Imel EA (2023) Approach to hypophosphatemic rickets. J Clin Endocrinol Metab 108:209\u2013220. https:\/\/doi.org\/10.1210\/clinem\/dgac488","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/26330040221074702","volume":"3","author":"MH Lafage-Proust","year":"2022","unstructured":"Lafage-Proust MH (2022) What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review. Ther Adv Rare Dis 3:1\u201310. https:\/\/doi.org\/10.1177\/26330040221074702","journal-title":"Ther Adv Rare Dis"},{"key":"2611_CR152","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1297\/cpe.18.29","volume":"18","author":"E Suzuki","year":"2009","unstructured":"Suzuki E, Yamada M, Ariyasu D, Izawa M, Miyamoto J, Koto S, Hasegawa Y (2009) Patients with hypophosphatemic osteomalacia need continuous treatment during adulthood. Clin Pediatr Endocrinol 18:29\u201333. https:\/\/doi.org\/10.1297\/cpe.18.29","journal-title":"Clin Pediatr Endocrinol"},{"key":"2611_CR153","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00268-010-0446-z","volume":"34","author":"AJ Kievit","year":"2010","unstructured":"Kievit AJ, Tinnemans JGM, Idu MM, Groothoff JW, Surachno S, Aronson DC (2010) Outcome of total parathyroidectomy and autotransplantation as treatment of secondary and tertiary hyperparathyroidism in children and adults. World J Surg 34:993\u20131000. https:\/\/doi.org\/10.1007\/s00268-010-0446-z","journal-title":"World J Surg"},{"key":"2611_CR154","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1210\/jcem.82.1.3666","volume":"82","author":"T Stefenelli","year":"1997","unstructured":"Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, Niederle B (1997) Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 82:106\u2013112. https:\/\/doi.org\/10.1210\/jcem.82.1.3666","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR155","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb YN (2018) Burosumab: first global approval. Drugs 78:707\u2013714. https:\/\/doi.org\/10.1007\/s40265-018-0905-7","journal-title":"Drugs"},{"key":"2611_CR156","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, Imel EA (2019) Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet 7:189\u2013199. https:\/\/doi.org\/10.1016\/S2213-8587(18)30338-3","journal-title":"Lancet"},{"key":"2611_CR157","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E et al (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393:2416\u20132427. https:\/\/doi.org\/10.1016\/S2213-8587(18)30338-3","journal-title":"Lancet"},{"key":"2611_CR158","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fped.2020.00048","volume":"8","author":"S Mart\u00edn Ramos","year":"2020","unstructured":"Mart\u00edn Ramos S, Gil-Calvo M, Rold\u00e1n V, Castellano Mart\u00ednez A, Santos F (2020) Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia. Front Pediatr 8:48. https:\/\/doi.org\/10.3389\/fped.2020.00048","journal-title":"Front Pediatr"},{"key":"2611_CR159","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","volume":"108","author":"R Padidela","year":"2021","unstructured":"Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward L, Nilsson O, Simmons PAA, JH, Namba N, Cheong HI, Pitukcheewanont P, Sochettet E, al. (2021) Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia. Calcif Tissue Int 108:622\u2013633. https:\/\/doi.org\/10.1007\/s00223-020-00797-x","journal-title":"Calcif Tissue Int"},{"key":"2611_CR160","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","volume":"107","author":"A Linglart","year":"2022","unstructured":"Linglart A, Imel EA, Whyte MP, Portale AA, H\u00f6gler W, Boot AM, Padidela R, van\u2019t Hoff W, Gottesman GS, Chen A, Skrinar A, Roberts MS, Carpenter TO (2022) Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107:813\u2013824. https:\/\/doi.org\/10.1210\/clinem\/dgab729","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jendso\/bvac021","volume":"6","author":"N Namba","year":"2022","unstructured":"Namba N, Kubota T, Muroya K, Tanaka H, Kanematsu M, Kojima M, Orihara S, Kanda H, Seino Y, Ozono K (2022) Safety and efficacy of burosumab in pediatric patients with X-linked hypophosphatemia: a phase 3\/4 open-label trial. J Endocr Soc 6:1\u201310. https:\/\/doi.org\/10.1210\/jendso\/bvac021","journal-title":"J Endocr Soc"},{"key":"2611_CR162","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s00467-022-05484-7","volume":"37","author":"NJ Paloian","year":"2022","unstructured":"Paloian NJ, Nemeth B, Sharafinski M, Modaff P, Steiner RD (2022) Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets. Pediatr Nephrol 37:2667\u20132677. https:\/\/doi.org\/10.1007\/s00467-022-05484-7","journal-title":"Pediatr Nephrol"},{"key":"2611_CR163","doi-asserted-by":"publisher","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","volume":"107","author":"LM Ward","year":"2022","unstructured":"Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, H\u00f6gler W, Simmons JH, Gottesman GS, Padidela R, Namba N, Cheong HI, Nilsson O, Mao M, Chen A, Skrinar A, Roberts MS, Imel EA (2022) Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107:e3241\u2013e3253. https:\/\/doi.org\/10.1210\/clinem\/dgac296","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.947814","volume":"13","author":"R Brener","year":"2022","unstructured":"Brener R, Zeitlin L, Lebenthal Y, Brener A (2022) Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy. Front Endocrinol 13:947814. https:\/\/doi.org\/10.3389\/fendo.2022.947814","journal-title":"Front Endocrinol"},{"key":"2611_CR165","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1007\/s00467-022-05822-9","volume":"38","author":"G Filler","year":"2023","unstructured":"Filler G, Tremblay O, Chen E, Shi Han Huang S, Stein R (2023) Sex differences of burosumab in children with X-linked hypophosphataemic rickets. Pediatr Nephrol 38:3183\u20133187. https:\/\/doi.org\/10.1007\/s00467-022-05822-9","journal-title":"Pediatr Nephrol"},{"key":"2611_CR166","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1007\/s00431-023-05190-y","volume":"182","author":"Y Levy-Shraga","year":"2023","unstructured":"Levy-Shraga Y, Levi S, Regev R, Gal S, Brener A, Lebenthal Y, Gillis D, Strich D, Zung A, Cleper R, Borovitz Y, Bello R, Tenenbaum A, Zadik Z, Davidovits M, Zeitlin L, Tiosano D (2023) Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study. Eur J Pediatr 182:5191\u20135202. https:\/\/doi.org\/10.1007\/s00431-023-05190-y","journal-title":"Eur J Pediatr"},{"key":"2611_CR167","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","volume":"108","author":"A Ewert","year":"2023","unstructured":"Ewert A, Rehberg M, Schlingmann KP, Hiort O, John-Kroegel U, Metzing O, W\u00fchl E, Schaefer F, Kemper MJ, Derichs U, Richter-Unruh A, Patzer L et al (2023) Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia. J Clin Endocrinol Metab 108:e998\u2013e1006. https:\/\/doi.org\/10.1210\/clinem\/dgad223","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR168","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/clinem\/dgad230","volume":"108","author":"EA Imel","year":"2023","unstructured":"Imel EA, Glorieux FH, Whyte MP, Portale AA, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E et al (2023) Burosumab vs phosphate\/active vitamin D in pediatric X-linked hypophosphatemia: a subgroup analysis by dose level. J Clin Endocrinol Metab 108:2990\u20132998. https:\/\/doi.org\/10.1210\/clinem\/dgad230","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR169","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/archdischild-2022-324962","volume":"108","author":"EYX Walker","year":"2023","unstructured":"Walker EYX, Alexander T, Lindsay J, Allgrove J, Marlais M, Bockenhauer D, Hayes W (2023) Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels. Arch Dis Child 108:379\u2013384. https:\/\/doi.org\/10.1136\/archdischild-2022-324962","journal-title":"Arch Dis Child"},{"key":"2611_CR170","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s12325-022-02412-x","volume":"40","author":"T Kubota","year":"2023","unstructured":"Kubota T, Namba N, Tanaka H, Muroya K, Imanishi Y, Takeuchi Y, Kanematsu M, Sun W, seino Y, Ozono K, (2023) Self-administration of burosumab in children and adults with X-linked hypophosphataemia in two open-label, single-arm clinical studies. Adv Ther 40:1530\u20131545. https:\/\/doi.org\/10.1007\/s12325-022-02412-x","journal-title":"Adv Ther"},{"key":"2611_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jbmrpl\/ziad001","volume":"8","author":"LM Ward","year":"2024","unstructured":"Ward LM, H\u00f6gler W, Glorieux FH, Portale AA, Whyte MP, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Sochett E et al (2024) Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period. JBMR Plus 8:1\u201314. https:\/\/doi.org\/10.1093\/jbmrpl\/ziad001","journal-title":"JBMR Plus"},{"key":"2611_CR172","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s44162-024-00034-1","volume":"3","author":"B Olivotto","year":"2024","unstructured":"Olivotto B, Djatougb\u00e9 Akolly E, Cabet S, Flammier S, Bertholet-Thomas A, de Mul A, Bacchetta J (2024) The effects of burosumab on growth, nephrocalcinosis and cardiovascular outcomes in children with X-linked hypophosphatemia: a single-center experience. J Rare Dis 3:10. https:\/\/doi.org\/10.1007\/s44162-024-00034-1","journal-title":"J Rare Dis"},{"key":"2611_CR173","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00467-024-06427-0","volume":"39","author":"M Klein","year":"2024","unstructured":"Klein M, Obermaier M, Mutze H, Wilden SM, Rehberg M, Schlingmann KP, Schmidt D, Metzing O, H\u00fcbner A, Richter-Unruh A, Kemper MJ, Weitz M et al (2024) Health-related quality of life of children with X-linked hypophosphatemia in Germany. Pediatr Nephrol 39:3221\u20133231. https:\/\/doi.org\/10.1007\/s00467-024-06427-0","journal-title":"Pediatr Nephrol"},{"key":"2611_CR174","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae079","author":"T Michigami","year":"2024","unstructured":"Michigami T, Kang HG, Namba N, Ito N, Kubota T, Shintani A, Kabata D, Kanematsu M, Nishida Y, Fukumoto S, Ozono K (2024) Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study. JBMR Plus. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae079","journal-title":"JBMR Plus"},{"key":"2611_CR175","doi-asserted-by":"publisher","first-page":"1487890","DOI":"10.3389\/fped.2024.1487890","volume":"12","author":"S Levi","year":"2024","unstructured":"Levi S, Landau D, Davidovits M, Rootman MS, Brener A, Gal S, Borovitz Y, Goldberg O, Bello R, Cleper R, Lebenthal Y, Levy-Shraga Y et al (2024) Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study. Front Pediatr 12:1487890","journal-title":"Front Pediatr"},{"key":"2611_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2024.101819","volume":"24","author":"C Jarvis","year":"2025","unstructured":"Jarvis C, Ramakrishnan R, Dharmaraj P, Mushtaq T, Gupta S, Williams A, Rylands AJ, Barhame H, Nixon A, Uday S (2025) Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH). Bone Rep 24:101819. https:\/\/doi.org\/10.1016\/j.bonr.2024.101819","journal-title":"Bone Rep"},{"key":"2611_CR177","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jpc.15976","volume":"58","author":"JL Sandy","year":"2022","unstructured":"Sandy JL, Simm PJ, Biggin A, Rodda CP, Wall CL, Siafarikas A, Munns CF (2022) Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab. J Paediatr Child Health 58:762\u2013768. https:\/\/doi.org\/10.1111\/jpc.15976","journal-title":"J Paediatr Child Health"},{"key":"2611_CR178","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.866170","volume":"13","author":"GT Mindler","year":"2022","unstructured":"Mindler GT, Stauffer A, Kranzl A, Penzkofer S, Ganger R, Radler C, Haeusler G, Raimann A (2022) Persistent lower limb deformities despite amelioration of rickets in X-linked hypophosphatemia (XLH): a prospective observational study. Front Endocrinol 13:866170. https:\/\/doi.org\/10.3389\/fendo.2022.866170","journal-title":"Front Endocrinol"},{"key":"2611_CR179","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/BP0.0b013e318273e411","volume":"32","author":"KH Sung","year":"2012","unstructured":"Sung KH, Ahn S, Chung CY, Lee KM, Kim TW, Han HS, Kim DH, Choi IH, Cho TJ, Yoo WJ, Park MS (2012) Rate of correction after asymmetrical physeal suppression in valgus deformity: analysis using a linear mixed model application. J Pediatr Orthop 32:805\u2013814. https:\/\/doi.org\/10.1097\/BP0.0b013e318273e411","journal-title":"J Pediatr Orthop"},{"key":"2611_CR180","doi-asserted-by":"publisher","first-page":"e899","DOI":"10.1097\/BPO.0000000000001970","volume":"41","author":"NT Kim","year":"2021","unstructured":"Kim NT, Kwon S-S, Choi KJ, Park MS, Chung JY, Han HS (2021) Sung KH (2021) Effect of screw configuration on the rate of correction for guided growth using the tension-band plate. J Pediatr Orthop 41:e899-903. https:\/\/doi.org\/10.1097\/BPO.0000000000001970","journal-title":"J Pediatr Orthop"},{"key":"2611_CR181","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/BPB.0000000000001054","volume":"33","author":"K Sawamura","year":"2024","unstructured":"Sawamura K, Hamajima T, Izawa M, Kaneko H, Kitamura A, Kitoh H (2024) Changes of the lower limb deformity in children with FGF23- related hypophosphatemic rickets treated with burosumab: a single-center prospective study. J Pediatr Orthop B 33:90\u201396. https:\/\/doi.org\/10.1097\/BPB.0000000000001054","journal-title":"J Pediatr Orthop B"},{"key":"2611_CR182","doi-asserted-by":"publisher","first-page":"1414509","DOI":"10.3389\/fendo.2024.1414509","volume":"15","author":"K Wang","year":"2024","unstructured":"Wang K, Zhang R, Chen Z, Bai Y, He Q (2024) Meta-analysis and systematic review: burosumab as a promising treatment for children with X-linked hypophosphatemia. Front Endocrinol 15:1414509. https:\/\/doi.org\/10.3389\/fendo.2024.1414509","journal-title":"Front Endocrinol"},{"key":"2611_CR183","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00223-024-01250-z","volume":"115","author":"D Kiafzezi","year":"2024","unstructured":"Kiafzezi D, Stamati A, Karagiannis T, Goulis DG, Christoforidis A (2024) Burosumab efficacy and safety in patients with X-linked hypophosphatemia: systematic review and meta-analysis of real-world data. Calcif Tissue Int 115:229\u2013241. https:\/\/doi.org\/10.1007\/s00223-024-01250-z","journal-title":"Calcif Tissue Int"},{"key":"2611_CR184","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s13023-022-02562-9","volume":"17","author":"DA Ertl","year":"2022","unstructured":"Ertl DA, Le Lorier J, Gleiss A, Trabado S, Bensignor C, Audrain C, Zhukouskaya V, Coutant R, Berkenou J, Rothenbuhler A, Haeusler G, Linglart A (2022) Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone. Orphanet J Rare Dis 17:412. https:\/\/doi.org\/10.1186\/s13023-022-02562-9","journal-title":"Orphanet J Rare Dis"},{"key":"2611_CR185","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10672","volume":"6","author":"M Gadion","year":"2022","unstructured":"Gadion M, Herv\u00e9 A, Herrou J, Rothenbuhler A, Smail-Faugeron V, Courson F, Linglart A, Chaussain C, Duplan MB (2022) Burosumab and dental abscesses in children with X-linked hypophosphatemia. JBMR Plus 6:e10672. https:\/\/doi.org\/10.1002\/jbm4.10672","journal-title":"JBMR Plus"},{"key":"2611_CR186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20406223241247643","volume":"15","author":"AB Boot","year":"2024","unstructured":"Boot AB, Ariceta G, Beck-Nielsen SS, Brandi ML, Briot K, de Lucas CC, Giannini S, Haffner D, Keen R, Levtchenko E, Mughal MZ, Makitie O et al (2024) Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis. Ther Adv Chronic Dis 15:1\u201315. https:\/\/doi.org\/10.1177\/20406223241247643","journal-title":"Ther Adv Chronic Dis"},{"key":"2611_CR187","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1515\/jpem-2020-0734","volume":"34","author":"D Harada","year":"2021","unstructured":"Harada D, Ueyama K, Oriyama K, Ishiura Y, Kashiwagi H, Yamada H, Seino Y (2021) Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets. J Pediatr Endocrinol Metab 34:791\u2013798. https:\/\/doi.org\/10.1515\/jpem-2020-0734","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2611_CR188","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ando.2023.07.108","volume":"84","author":"V Zhukouskaya","year":"2023","unstructured":"Zhukouskaya V, Ertl DA, Berkenou J, Audrain C, Bardet C, Chaussain C, Rothenbuhler A, Linglart A (2023) Hyperparathyroidism after 3 years of burosumab in children affected with X-linked hypophosphatemia. Ann Endocr 84:544. https:\/\/doi.org\/10.1016\/j.ando.2023.07.108","journal-title":"Ann Endocr"},{"key":"2611_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117324","volume":"190","author":"R Padidela","year":"2025","unstructured":"Padidela R, Rayner L, Boot AM (2025) Tertiary hyperparathyroidism in two paediatric patients with X-linked hypophosphatemia during burosumab treatment. Bone 190:117324. https:\/\/doi.org\/10.1016\/j.bone.2024.117324","journal-title":"Bone"},{"key":"2611_CR190","doi-asserted-by":"publisher","first-page":"344","DOI":"10.4274\/jcrpe.galenos.2021.2020.0287","volume":"14","author":"A Castellano-Martinez","year":"2022","unstructured":"Castellano-Martinez A, Acunas-Soto S, Roldan-Cano V, Rodriguez-Gonzalez M (2022) Left ventricular hypertrophy in patients with X-linked hypophosphataemia. J Clin Res Pediatr Endocrinol 14:344\u2013349. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2021.2020.0287","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"2611_CR191","doi-asserted-by":"publisher","first-page":"1400273","DOI":"10.3389\/fendo.2024.1400273","volume":"15","author":"A Brener","year":"2024","unstructured":"Brener A, Cleper R, Baruch G, Rothschild E, Yackobovitch-Gavan M, Beer G, Zeitlin L, Kapusta L (2024) Cardiovascular health in pediatric patients with X-linked hypophosphatemia under two years of burosumab therapy. Front Endocrinol 15:1400273. https:\/\/doi.org\/10.3389\/fendo.2024.1400273","journal-title":"Front Endocrinol"},{"key":"2611_CR192","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00223-022-01006-7","volume":"11","author":"ML Brandi","year":"2022","unstructured":"Brandi ML, Jan de Beur S, Briot K, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Imel EA, Ing SW, Insogna K et al (2022) Efficacy of burosumab in adults with X-linked hypophosphatemia (XLH): a post hoc subgroup analysis of a randomized double-blind placebo-controlled phase 3 study. Calcif Tissue Int 11:409\u2013418. https:\/\/doi.org\/10.1007\/s00223-022-01006-7","journal-title":"Calcif Tissue Int"},{"key":"2611_CR193","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002676","volume":"9","author":"P Kamenicky","year":"2023","unstructured":"Kamenicky P, Briot K, Brandi ML, Cohen-Solal M, Crowley RK, Keen R, Kolta S, Lachmann RH, Lecoq AL, Ralston SH, Walsh JS, Rylandset AJ, al. (2023) Benefit of burosumab in adults with X- linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD Open 9:e002676. https:\/\/doi.org\/10.1136\/rmdopen-2022-002676","journal-title":"RMD Open"},{"key":"2611_CR194","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae890","author":"DS Ali","year":"2024","unstructured":"Ali DS, Mirza RD, Alsarraf F, Hussein S, Abu Alrob H, Appelman-Dijkstra NM, Beck-Nielsen SS, Biosse-Duplan M, Brandi ML, Carpenter TO, Chaussain C, Cohen-Solal M et al (2024) Systematic review: efficacy of medical therapy on outcomes important to adult patients with X-linked hypophosphatemia. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae890","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR195","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenicky P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1383\u20131393. https:\/\/doi.org\/10.1002\/jbmr.3475","journal-title":"J Bone Miner Res"},{"key":"2611_CR196","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter TO, Ml B, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S et al (2019) Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int 105:271\u2013284. https:\/\/doi.org\/10.1007\/s00223-019-00568-3","journal-title":"Calcif Tissue Int"},{"key":"2611_CR197","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10074","volume":"3","author":"HI Cheong","year":"2019","unstructured":"Cheong HI, Yoo HW, Adachi M, Tanaka H, Fujiwara I, Hasegawa Y, Harada D, Sugimoto M, Okada Y, Karto M, Shimazaki R, Ozono K, Seino Y (2019) First-in-Asian phase I study of the anti-fibroblast growth factor 23 monoclonal antibody, burosumab: safety and pharmacodynamics in adults with X-linked hypophosphatemia. JBMR Plus 3:e10074. https:\/\/doi.org\/10.1002\/jbm4.10074","journal-title":"JBMR Plus"},{"key":"2611_CR198","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fendo.2020.00338","volume":"11","author":"C Schindeler","year":"2020","unstructured":"Schindeler C, Biggin A, Munns CF (2020) Clinical evidence for the benefits of burosumab therapy for X-linked hypophosphatemia (XLH) and other conditions in adults and children. Front Endocrinol 11:338. https:\/\/doi.org\/10.3389\/fendo.2020.00338","journal-title":"Front Endocrinol"},{"key":"2611_CR199","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/clinem\/dgac518","volume":"108","author":"TJ Weber","year":"2023","unstructured":"Weber TJ, Imel EA, Carpenter TO, Peacock M, Portale AA, Hetzer J, Merritt JL, Insogna K (2023) Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia. J Clin Endocrinol Metab 108:155\u2013165. https:\/\/doi.org\/10.1210\/clinem\/dgac518","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR200","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.3390\/jcm12082906","volume":"12","author":"T Arcidiacono","year":"2023","unstructured":"Arcidiacono T, Foligno NE, Brioni E, Bologna A, Weber G, Mora S, Pitea M, Vitale C, Vezzoli G (2023) Different efficacy of burosumab on physical performance and serum phosphate in adult patients with X-linked hyphophosphatemic rickets during the first six-month of treatment. J Clin Med 12:2906. https:\/\/doi.org\/10.3390\/jcm12082906","journal-title":"J Clin Med"},{"key":"2611_CR201","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jcph.570","volume":"56","author":"X Zhang","year":"2016","unstructured":"Zhang X, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey J, Glorieux FH, Portale AA, Insogna K, Carpenter TO, Peacock M (2016) Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J Clin Pharmacol 56:176\u2013185. https:\/\/doi.org\/10.1002\/jcph.570","journal-title":"J Clin Pharmacol"},{"key":"2611_CR202","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna KL, Rauch F, Kamenick\u00fd P, Ito N, Kubota T, Nakamura A, Zhang L, Mealiffe M, San Martin J, Portale AA (2019) Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res 34:2183\u20132191. https:\/\/doi.org\/10.1002\/jbmr.3843","journal-title":"J Bone Miner Res"},{"key":"2611_CR203","doi-asserted-by":"publisher","first-page":"e1061","DOI":"10.1210\/clinem\/dgad642","volume":"109","author":"KL Insogna","year":"2024","unstructured":"Insogna KL, Sullivan R, Parziale S, Deng Y, Carrano D, Simpson C, Dufour S, Carpenter TO, Petersen KF (2024) Effect of burosumab on muscle function and strength, and rates of ATP synthesis in skeletal muscle in adults with XLH. J Clin Endocrinol Metab 109:e1061\u2013e1071. https:\/\/doi.org\/10.1210\/clinem\/dgad642","journal-title":"J Clin Endocrinol Metab"},{"key":"2611_CR204","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","volume":"5","author":"MD Ruppe","year":"2016","unstructured":"Ruppe MD, Zhang X, Imel EA, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO (2016) Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep 5:158\u2013162. https:\/\/doi.org\/10.1016\/j.bonr.2016.05.004","journal-title":"Bone Rep"},{"key":"2611_CR205","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001714","volume":"7","author":"K Briot","year":"2021","unstructured":"Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N et al (2021) Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open 7:e001714. https:\/\/doi.org\/10.1136\/rmdopen-2021-001714","journal-title":"RMD Open"},{"key":"2611_CR206","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/cpt.3406","volume":"116","author":"K Mehta","year":"2024","unstructured":"Mehta K, Gosselin NH, Insogna K, Barriere O, Quattrocchi E, Hruska MW, Marsteller D (2024) Item response theory quantifies the relationship between improvements in serum phosphate and patient-reported outcomes in adults with X-linked hypophosphatemia. Clin Pharmacol Ther 116:1343\u20131351. https:\/\/doi.org\/10.1002\/cpt.3406","journal-title":"Clin Pharmacol Ther"},{"key":"2611_CR207","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jcph.6140","volume":"65","author":"K Mehta","year":"2025","unstructured":"Mehta K, Storopoli J, Ramwani N, Quattrocchi E, Gobburu J, Weber T, Hruska MW, Marsteller D (2025) Pharmacodynamic XLH exposure-response analysis of fracture count data following treatment with burosumab in patients with XLH. Clin Pharmacol Ther 65:253\u2013260. https:\/\/doi.org\/10.1002\/jcph.6140","journal-title":"Clin Pharmacol Ther"},{"key":"2611_CR208","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1515\/jpem-2021-0217","volume":"34","author":"GI Baroncelli","year":"2021","unstructured":"Baroncelli GI, Bertelloni S, Cosci o di Coscio M, Tyutyusheva N, D\u2019Elios S, Peroni D, (2021) Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown. J Pediatr Endocrinol Metab 34:905\u2013910. https:\/\/doi.org\/10.1515\/jpem-2021-0217","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2611_CR209","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/clinem\/dgab796","volume":"107","author":"K Dahir","year":"2022","unstructured":"Dahir K, Dhaliwal R, Simmons J, Imel EA, Gottesman GS, Mahan JD, Prakasam G, Hoch AI, Ramesan P, Diaz-Gonzales de Ferris M (2022) Health care transition from pediatric- to adult- focused care in X-linked hypophosphatemia: expert consensus. J Clin Endocrinol Metab 107:599\u2013613. https:\/\/doi.org\/10.1210\/clinem\/dgab796","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"2611_CR210","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s13023-024-03387-4","volume":"19","author":"L Seefried","year":"2025","unstructured":"Seefried L, Aliberti F, Heier CA, Arango-Sancho P, Biosse Duplan M, Sakka SD, Emma F, Gardiner O, Javaid MK, Ferreira-Santos RM, Raimann A, Rak K et al (2025) XLH Matters: an evolving programme to discuss new advances and share clinical experiences to improve patient outcomes. Orphanet J Rare Dis 19(Suppl 2):497. https:\/\/doi.org\/10.1186\/s13023-024-03387-4","journal-title":"Orphanet J Rare Dis"},{"key":"2611_CR211","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-023-02698-2","volume":"18","author":"C Grasemann","year":"2023","unstructured":"Grasemann C, H\u00f6ppner J, Burgard P, Sch\u00fcndeln MM, Matar N, M\u00fcller G, Krude H, Berner R, Lee-Kirsch MA, Hauck F, Wainwright K, Baumgarten S et al (2023) Transition for adolescents with a rare disease: results of a nationwide German project. Orphanet J Rare Dis 18:93. https:\/\/doi.org\/10.1186\/s13023-023-02698-2","journal-title":"Orphanet J Rare Dis"},{"key":"2611_CR212","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/endocrines3030032","volume":"3","author":"T Kubota","year":"2022","unstructured":"Kubota T (2022) X-linked hypophosphatemia transition and team management. Endocrines 3:411\u2013418. https:\/\/doi.org\/10.3390\/endocrines3030032","journal-title":"Endocrines"}],"updated-by":[{"DOI":"10.1007\/s40618-025-02703-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000}}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02611-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02611-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02611-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T18:03:47Z","timestamp":1760465027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02611-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":212,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["2611"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02611-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40618-025-02703-4","asserted-by":"object"}]},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: due to author names were incorrectly structured in the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40618-025-02703-4","URL":"https:\/\/doi.org\/10.1007\/s40618-025-02703-4","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All Authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}